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with rheumatoid arthritis by ultrasound:
an agreement study exploring the most
inflammatory active side from two
Norwegian trials
Lene Terslev1,2* , Robin Christensen2,3, Anna-Birgitte Aga4, Joe Sexton4, Espen A. Haavardsholm4,5 and
Hilde B. Hammer4
Abstract
Objective: To assess if the right hand, the dominant hand, or the hand with more clinically swollen joints (SwJ) is
per se the most inflamed and exhibits the greatest change during treatment and hence preferred for unilateral
scoring of synovitis by ultrasound in rheumatoid arthritis (RA) patients.
Methods: Using data from two previously published Norwegian RA patient cohorts initiating treatment, bilateral
metacarpophalangeal joint 1–5, proximal phalangeal joint 2+3, and wrists were evaluated by ultrasound. Using a
0–3 scoring system a grey-scale (GS), power Doppler (PD) and global synovitis score (GLOESS) was calculated for
each hand (0–30). For precision, a difference of < ± 3 in sum score was pre-specified as indicating clinically
insignificant difference in inflammatory activity for all three scores.
Results: Four hundred thirty-seven RA patients were included. Baseline ultrasound inflammation was statistically
significantly higher in hands with more vs fewer SwJ ([mean difference, 95%CI] GS sum score 2.21[1.30 to 3.12], PD sum
score 1.70 [0.94 to 2.47] and GLOESS 2.31[1.36 to 3.26]) and also exhibited significantly more change for all sum scores
at 3 months follow-up (GS sum score 1.34 [0.60 to 2.08], PD sum score 1.17 [0.44 to 1.91], and GLOESS 1.43 [0.63 to
2.22]). No such differences were found between the dominant and the non-dominant or the right and the left hands
at any time points.
Conclusion: The hand with clinically more SwJ is statistically more inflammatory active according to GS, Doppler, and
GLOESS sum scores, exhibits a change during treatment, and is potentially the best choice for unilateral
scoring systems.
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Background
Ultrasound has been validated as an outcome measure-
ment tool for assessing synovitis by grey-scale (GS) and
Doppler in rheumatoid arthritis (RA) [1, 2]. Though re-
cent publications have indicated that ultrasound examin-
ation of all RA patients—if offered a very tight clinical
control—may not be necessary for obtaining clinical re-
mission [3, 4], there are several situations in the clinic
where ultrasound has a role in monitoring synovitis as
an indicator of disease activity. Furthermore, ultrasound
is used in clinical trials for assessing treatment response
and remission. The components defining synovitis (syn-
ovial hypertrophy and hyperemia) are usually scored
separately using a semi-quantitative scoring system (0–
3) for indicating the grade of severity of the individual
synovitis component [5]. In the recently published
OMERACT-EULAR combined scoring system [1], it is
suggested to apply the highest score of the two compo-
nents as the final score for the joint. Scoring GS synovial
hypertrophy and Doppler activity separately or in com-
bination is sensitive to change during treatment both on
joint and patient level—for the latter using a sum score
[6]. When applied in a clinical trial context, several re-
duced joint sets, ranging from 6 to 12 joints, have been
proposed for scoring synovitis over the last years [7–11].
These reduced joint sets evaluate synovitis either unilat-
erally or bilaterally, aiming at maintaining as much in-
formation about the inflammatory load of the patient as
seen in the more elaborate and time-consuming joint
evaluations (32–78 joints) [12, 13].
Scoring synovitis unilaterally will by far reduce the
examination time [9], and the unilateral 7-joint count by
Backhaus et al. [7] is often used in trials. In unilateral
scoring systems, the suggestion is to choose either the
dominant side [7, 8] or the clinically most affected side
defined as the hand with the most tender and/or swollen
joints [9, 14, 15]. The dominant side is also commonly
the chosen side in magnetic resonance imaging (MRI),
where only one side can be evaluated at a time and is
based on data showing that the dominant hand has
more erosions on X-ray than the non-dominant hand
both at baseline and follow-up [16, 17]. However,
there is no evidence per se to support the dominant
hand as being more inflammation prone than the
non-dominant hand at time of treatment initiation.
Because of the lack of evidence-based guidance, we
decided to assess which selection is likely to identify
the more inflamed hand, a research-on-research pro-
ject that could provide information about RA presen-
tation of inflammation and could potentially serve as
a guide for the “default option” in unilateral scoring
systems among ultrasonographers in rheumatology
and thus ensure better homogeneity among future
studies and clinical reports.
The primary aim of this study was to investigate if one
hand is always more inflamed than its counterpart as
this would have implications for a unilateral scoring sys-
tem applied in the clinic and for the application in clin-
ical trials. This was assessed by evaluating if the right
hand, the dominant hand (as indicated by MRI), or the
hand with clinically more swollen joints is more likely to
have higher ultrasound measured inflammation than its
counterpart at the time of inclusion, as well as for
changes during treatment from baseline to 3 months
follow-up.
Patients and methods
This research-on-research project was performed ac-
cording to a pre-defined Statistical Analysis Plan that
was uploaded in advance (see Additional file 1). The
study was designed to identify at baseline the hand with
most ultrasound-verified inflammation and hence most
appropriate for potential unilateral ultrasound assess-
ment, and further to investigate the change in inflamma-
tion of this selection at 3 months follow-up. Hence, the
follow-up study was not about assessing treatment effect
over time, but about evaluating the ability of the inflam-
mation to change.
This study is a result of secondary analyses based on two
independent ultrasound datasets including an early RA
cohort (ARCTIC trial; ClinicalTrials.gov database
[NCT01581294]) and an established RA cohort (ULRABIT
trial; Anzctr.org.au database [ACTRN12610000284066])
initiating conventional synthetic disease-modifying anti-
rheumatic drugs (DMARDs) in the early cohort and initiat-
ing or switching biological DMARD (bDMARD) in the
established cohort. From the ARCTIC trial (recruited be-
tween September 2010 and April 2013), 238 patients with
early RA were included, and in the ULRABIT trial (re-
cruited from January 2010 to June 2013), 212 patients with
established RA were included.
Ultrasonography assessments
In these analyses, the hands were used as model evaluat-
ing metacarpophalangeal joint (MCP) 1–5, proximal in-
terphalangeal joint (PIP) 2 and 3, and the wrist. The
selection of PIP joints was based on the study of Back-
haus et al. [7]. In the original ULRABIT trial, extensive
ultrasound examinations were performed by a single ex-
perienced sonographer, and in the ARCTIC trial, by sev-
eral experienced sonographers who had been trained in
annual ultrasound workshops with both static and dy-
namic hands-on exercises to calibrate readers. In both
studies, synovitis was defined hypoechoic synovial hyper-
trophy with or without Doppler activity including all
hypoechogenic tissue inside the joint capsule as syno-
vitis. Though effusion may be hypoechoic, it is mostly
anechoic and a rare finding in RA wrists and finger
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joints in contrast to knees and MTP joints and therefore
not likely to influence the current analysis. Hence for
the hands, the definition for synovitis is in line with the
modified OMERACT definition [1].
A 0–3 semiquantitative scoring system for both GS and
power Doppler findings was applied in each of the follow-
ing 36 joints: MCP 1–5, PIP 2–3, radiocarpal, midcarpal,
distal radioulnar, elbow, knee, talocrural, and metatarso-
phalangeal (MTP) 1–5 bilaterally using the ultrasound
atlas by Hammer et al. as a reference which had demon-
strated a high inter- and intra-observer reliability [18]. In
the ULRABIT study, a Siemens Antares Sonoline machine
was used (Siemens Medical solutions, Mountain view,
CA, USA) with a linear probe (5–13MHz and setting at
11.4MHz) and unchanged Doppler settings optimized for
slow flow [19]. In the ARTIC study, the same Siemen An-
tares Sonoline machines or GE Logiq E9’s (GE Medical
Systems Ultrasound and Primary Care Diagnostics, Wau-
watose, WI, USA) were used at baseline and follow-up in
the participating centers (11 hospitals), all with linear
probes and identical unchanged Doppler settings opti-
mized for slow flow [19].
In the current analyses, both GS and power Doppler
sum scores, as well as the OMERACT-EULAR com-
bined score (GLOESS) [1], were calculated for each hand
(for all sum scores, the range is 0–30). The highest score
of GS and PD was defined as the GLOESS score for the
individual joint.
A difference of less than 3 in ultrasound sum scores be-
tween the hands was perceived by the authors to be clinic-
ally insignificant based on expert opinion and was
prespecified in the statistical analysis plan (Additional file 1)
.
Laboratory and clinical examinations
For both trials, each visit included laboratory assessments
of erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP, mg/L) and 0–100-mm visual analogue scales
(VAS) for assessor’s and patient’s global assessments of
disease activity. In the ARTIC study, anticyclic citrulli-
nated peptide (anti-CCP) and rheumatoid factor (RF) was
assessed at baseline whereas this had been assessed prior
to the study for the ULRABITcohort. For the early RA co-
hort, 44 swollen joint counts (44 SJC) and Ritchie Articu-
lar Index were performed, while 28 swollen and tender
joint counts (28 SJC and 28 TJC, respectively) were per-
formed in the established RA cohort. The Disease Activity
Score (DAS) was calculated in the early RA cohort,
whereas the DAS28 was calculated in the patients with
established RA; both scores were based on ESR.
Statistical methods
In this agreement study, our objective was to see
whether various approaches showed sufficient agreement
to be applied interchangeably. Our initial approach was
based on the Bland-Altman graphical techniques [20] to
visually present a potential pattern between left versus
right hand as the plot of difference against the mean of
the two. This step also included a plot of the data and
draw the line of equality on which all points would lie if
the two ultrasound measures (left versus right) gave
exactly the same reading every time. This scatter plot
helps the eye in gauging the degree of agreement be-
tween measurements. Also, we use a plot of difference
(right versus left) against mean which allows us to inves-
tigate any possible relationship between the measure-
ment error and the true value. By calculating mean
difference (Δ: left − right) and the standard deviation of
the differences (SDΔ), we would expect most of the dif-
ferences to lie between Δ ± 1.96 × SDΔ if the differences
are normally distributed where 95% of differences will lie
between these limits [20].
According to our prespecified statistical analysis plan
(Additional file 1), we wanted to evaluate whether there
is a potential difference in ultrasound inflammation or
two contextual factors: dominant hand and the hand
with most swollen joints, respectively. Using SAS for
Mixed Models (PROC MIXED), the similarity between
measures was tested. The mixed effect model took into
account any differences in patient characteristics (e.g.,
disease duration) between groups by including a fixed
factor for cohort (i.e., adjusting for the “cohort effect”).
The least squares mean values and the difference be-
tween them are reported based on a statistical model in-
cluding a factor for the specific analysis (i.e., dominant/
right/swollen), and trial (ARCTIC and ULRABIT, re-
spectively) as fixed effects, with the patient-ID as a ran-
dom effect. We a priori defined a reasonable equivalence
margin between measures, to be a 95% confidence inter-
val around the observed paired mean difference: − 2.99
to + 2.99 (Additional file 1).
Results
Baseline and follow-up demographics for the combined
cohort as well as for the sub-cohorts are shown in
Table 1. The total cohort consisted of 442 patients and
comprised the ARCTIC cohort with 230 DMARD naïve
patients with early RA with indication for methotrexate
(as 8 of the original 238 patients were subsequently ex-
cluded from the study as they did not receive treatment)
and the ULRABIT cohort with 212 established RA pa-
tients with indication for bDMARDs.
Of the 442 patients, only 437 (99%) were included in
the ultrasound evaluation as five patients from the
ARTIC cohort were enrolled without an ultrasound
examination at baseline whereas all 212 patients in the
ULRABIT cohort had an ultrasound examination at time
of inclusion. At 3 months follow-up, 295 patients had an
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ultrasound examination—116 patients from the ARTIC
study and 179 patients from the ULRABIT study. For
the whole cohort, 21 (5%) patients had left hand domin-
ance and 410 (95%) had right hand dominance, and for
11 patients, the information was missing. Similarly, for
the whole cohort, 183 (42%) patients had the right hand
as the most clinically affected hand and 131 (30%) had
the left hand as the most affected hand at time of treat-
ment initiation, and for 123 (28%) patients, both hands
were clinically equally affected (same number of swollen
joints in both hands), and for one patient, the clinical
joint information was missing.
Differences in inflammatory activity between hands
To assess if any systematic errors could potentially be
found between the right- and left-hand side, Bland-
Altman scatter plots were made (Fig. 1) to give a visual
impression of potential differences and to assess if fur-
ther analysis should be carried out. Though there
seemed to be an even distribution between the right and
the left hand for the GS sum score, Doppler sum score,
and the GLOESS score, the right hand appeared to be
potentially more involved for all three sum scores than
the left.
Subsequent analyses were carried out to assess if the
potential differences were present between the dominant
and non-dominant hands, the right and the left hands,
and the more clinically affected hand and the less clinic-
ally affected. The analyses of differences in sum scores
between the dominant versus the non-dominant hand
revealed that the dominant hand was not more inflam-
matory active than the non-dominant (mean difference,
95%CI) for GS sum score − 0.69 (− 1.61 to 0.24; p = 0.15;
both confidence limits within the equivalence margin),
power Doppler sum score − 0.58 (− 1.35 to 0.20; p =
0.14; both confidence limits within the equivalence mar-
gin), and GLOESS − 0.79 (− 1.76 to 0.18; p = 0.11; both
confidence limits within the equivalence margin)
(Table 2). Similar results were found for the right versus
left hand where the mean difference for the GS sum
score was − 0.75 (− 1.68 to 0.18; p = 0.11; both confi-
dence limits within the equivalence margin), for the
power Doppler sum score − 0.61 (− 1.38 to 0.16; p =
0.12; both confidence limits within the equivalence mar-
gin) and for the GLOESS − 0.89 (− 1.85 to 0.08; p = 0.07;
both confidence limits within the equivalence margin).
When analyzing the importance of SwJ in the 314 of
the 437 patients having differences in SwJ between the
two sides, the analyses of the hand with more swollen
joints showed a statistically significant difference in in-
flammatory activity as compared to the hand with less
swollen joints for all three US variables: GS sum score
2.21 (1.30 to 3.12; p < .0001), Doppler sum score 1.70
(0.94 to 2.47; p < .0001), and GLOESS 2.31(1.36 to 3.26;
p < .0001). However, with the pre-specified clinically im-
portant difference of 3 in sum scores, only the GS and
GLOESS sum score may have a clinical impact whereas
only a borderline clinical significance was found for the
Doppler sum score as the upper confidence limit was
lower than the equivalence margin of 3.
Differences in inflammatory activity assessed over time
Clinically, there was a significant change in DAS for
the ARCTIC cohort and in DAS28 (ESR) for the
ULRABIT cohort from baseline to 3 months (for
ARCTIC (mean (SD)) − 1.75 (0.94) and for ULRABIT
− 1.08 (1.26) – p < 0.001 for both) [4].
Differences in (exhibiting a) change during treatment
were assessed for GS sum score, Doppler sum score, and
GLOESS for the dominant versus the non-dominant
hand, the right versus left hand, and the clinically more
affected hand versus the less clinically affected hand
(Table 2) and found that the clinically more affected
hand changed more than the less clinically affected hand
(mean difference, 95%CI) for GS sum core 1.34 (0.60 to
2.08; p < 0.0004), Doppler sum score 1.17 (0.44 to 1.91,
p < 0.002) and GLOESS 1.43 (0.63 to 2.22; p < 0.0005).
No differences in change over time were found for the
right versus left hand and the dominant versus the non-
dominant hand.
Discussion
In this agreement study comprising both early and
established RA patients, we assessed differences in in-
flammatory activity in the right hand, the dominant
hand, and the hand with clinically more swollen joints as
compared to its counterpart. We found that the clinic-
ally more affected hand at baseline (determined as the
hand with more clinically swollen joints) was also the
more inflammatory active side—independent of using
GS sum score, Doppler sum score, or the GLOESS.
Similarly, the clinically most affected side was also found
to be the hand exhibiting a greater change for all sum
scores during treatment. These findings are to some ex-
tent in line with the subset of studies applying the uni-
lateral 7-joint score where the most affected hand
evaluated is the hand with the most swollen and/or ten-
der joint—in these studies, this hand was sensitive to
change after onset or switch of therapy (DMARDs and/
or biologic) [10, 11]. In the current study, we did not
evaluate the differences in inflammatory activity between
hands with more and less tender joints as tender joints
in contrast to swollen joints are not necessarily related
to inflammatory joint involvement [21–24].
In clinical trials and in a daily clinical setting when
assessing a treatment effect, it is common practice to
choose the most inflamed joints for evaluation as they
are more likely to exhibit a change during treatment. It
Terslev et al. Arthritis Research & Therapy          (2019) 21:166 Page 5 of 9
was therefore of interest to evaluate if for unilateral as-
sessment one hand was by nature always more inflamed
than its counterpart based solely, i.e., on handedness as
this would have impact on clinical trials and for stan-
dardized assessments in the clinic. Based on the findings
in this research-on-research study applying a clinically
significant cutoff of 3 in ultrasound sum scores, a default
decision cannot be made on which side to scan. A clin-
ical joint evaluation for SwJ is mandatory for choosing
the optimal side for assessing treatment effect. However,
the predictive value of ultrasound for treatment response
and for obtaining remission has yet to be determined.
Our data may however be used in subsequent prognostic
factor research to explore whether the most involved
hand is more appropriate (than any arbitrary decision)
when trying to predict outcomes in longitudinal cohort
studies and to predict who will benefit from new poten-
tial effective drugs.
As the dominant hand is often chosen in MRI studies
based on reports that this hand is having more erosive
changes over time [16, 17], one could speculate that this
would be linked to the dominant hand being more in-
flammatory active than the non-dominant hand. In
ultrasound studies, higher levels of inflammation in RA
patients with both active disease and in remission have
been shown to be related to erosive progression [25–27];
however, we were not able to show that the dominant
hand was significantly more inflammatory active than
the non-dominant hand nor was there any difference per
se in inflammatory activity between the right and left
Fig. 1 Bland-Altman plot of the distribution of the Doppler sum score, Global synovitis score (GLOESS) sum score, and grey-scale (GS) sum score
for right and left hands. a Scatter plot: Doppler sum score ultrasound measured on the right and the left hand, with line of equality. b Bland-
Altman plot: Difference against mean for Doppler sum score data. c Scatter plot: GLOESS sum score measured on the right and the left hands,
with line of equality. d Bland-Altman plot: Difference against mean for GLOSS sum score data. e Scatter plot: GS sum score measured on the right
and the left hands, with line of equality. f Bland-Altman plot: Difference against mean for GSUS sum score data
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hands. During treatment, neither the dominant hand nor
the right hand displayed significantly greater change
than the opposite hand.
Reduced joint combinations when using a 78-joint
score as gold standard all respond well to biological
treatment and all seem to give comparable information
about the inflammatory activity in RA patients as a com-
prehensive ultrasound examination [12]. The best re-
duced set of joints have yet to be established [13], and
though bilateral joint examinations better retain the in-
flammatory load of the patients than a unilateral evalu-
ation [8], there is an interest in reducing examination
time for feasibility reasons in daily clinical practice but
also in clinical trials when applying ultrasound as an
outcome measurement instrument. One of the often-
mentioned reasons for the hampered implementation of
ultrasound in the clinic is the lack of time. The current
study has used the hands as a model as they are involved
in all reduced joint sets [7–11], and examination solely
of the hands has previously been shown to detect more
than 91% of RA patients in remission with subclinical
inflammation [28] and hence appears to retain valuable
information about the inflammatory load of the patient.
Though much emphasis has been put on the presence
of Doppler activity for assessing the degree of inflamma-
tion [3, 4], it has recently been demonstrated that also
synovial hypertrophy without Doppler activity may
change during treatment [29, 30], and it is therefore in-
teresting that the most affected side for synovitis is inde-
pendent of applying GS sum score or the GLOESS. The
Doppler sum score showed statistically but only border-
line clinical significance. This supports that both aspects
of the synovitis complex (GS synovial hypertrophy and
Doppler activity) are important and that if choosing uni-
lateral scoring systems even when working with an ultra-
sound equipment with an insensitive Doppler, it is still
the hand with the most swollen joints that should be
chosen at time of evaluation and for follow-up.
In the current study, we applied a cutoff for clinically
important differences in sum score of 3 for synovial
hypertrophy, Doppler and GLOESS between the two
hands based on expert opinion. One could argue that a
lower cutoff would be equally correct, but we chose a
stricter approach resulting in GS and GLOESS sum
scores showing clinical and statistical differences be-
tween the hand with more and less SwJ. The Doppler
Table 2 Ultrasound inflammatory activity in the dominant hand versus the non-dominant hand, in the hand with clinically more
swollen joint versus less swollen joints, and in the right hand versus left hand using different composite scores for the early and
established RA cohorts combined
Baseline Change values from baseline to 3 months
GS sum score
(0–30)
Doppler sum
score (0–30)
GLOESS (0–30) Δ GS sum
score (0–30)
Δ Doppler sum
score (0–30)
Δ GLOESS (0–30)
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
*Dominant hand (n = 431)
Dominant 7.75 (7.09 to 8.40) 4.81 (4.26 to 5.35) 8.07 (7.39 to 8.75) − 3.11
(− 3.65 to − 2.57)
− 2.57
(− 3.10 to − 2.04)
− 3.40
(− 3.98 to − 2.82)
Non-dominant 7.06 (6.41 to 7.72) 4.22 (3.68 to 4.78) 7.28 (6.60 to 7.96) − 3.12
(− 3.66 to − 2.58)
− 2.35
(− 2.88 to − 1.82)
− 3.29
(− 3.87 to − 2.71)
Difference − 0.69 (− 1.61 to 0.24) − 0.58 (− 1.35 to 0.20) − 0.79 (− 1.76 to 0.18) − 0.005
(− 0.76 to 0.75)
0.22
(− 0.52 to 0.96)
0.11
(− 0.70 to 0.92)
P value 0.15 0.14 0.11 0.99 0.57 0.79
*Clinical hand (n = 314)
Worst clinical
(more SJC)
8.51 (7.87 to 9.16) 5.37 (4.83 to 5.91) 8.83 (8.16 to 9.50) − 3.79
(− 4.32 to − 3.25)
− 3.05
(− 3.57 to − 2.52)
− 4.06
(− 4.63 to − 3.49)
Least clinical
(fewer SJC)
6.30 (5.65 to 6.94) 3.66 (3.13 to 4.20) 6.52 (5.85 to 7.19) − 2.45
(− 2.98 to − 1.92)
− 1.87
(− 2.40 to − 1.35)
− 2.64
(− 3.21 to − 2.06)
Difference − 2.21 (− 3.12 to − 1.30) − 1.70 (− 2.47 to − 0.94) − 2.31 (− 3.26 to − 1.36) 1.34 (0.60 to 2.08) 1.17 (0.44 to 1.91) 1.43 (0.63 to 2.22)
P value < .0001 < .0001 < .0001 0.0004 0.002 0.0005
*Hand side (n = 437)
Right side 7.78 (7.12 to 8.44) 4.82 (4.28 to 5.37) 8.12 (7.44 to 8.80) − 3.19
(− 3.73 to − 2.65)
− 2.64
(− 3.17 to − 2.11)
− 3.49
(− 4.07 to − 2.91)
Left side 7.03 (6.37 to 7.68) 4.21 (3.6 to 4.76) 7.23 (6.55 to 7.91) − 3.05
(− 3.59 to − 2.51)
− 2.28
(− 2.81 to − 1.75)
− 3.21
(− 3.78 to − 2.63)
Difference − 0.75 (− 1.68 to 0.18) − 0.61 (− 1.38 to 0.16) − 0.89 (− 1.85 to 0.08) 0.14
(− 0.61 to 0.89)
0.36
(− 0.38 to 1.10)
0.29
(− 0.52 to 1.09)
P value 0.11 0.12 0.07 0.71 0.34 0.49
*Analyzed using a factor for the specific analyses (dominant, clinical and hand, respectively), and trial (ARCTIC and ULRABIT, respectively) as fixed effects, and the patient-ID
was applied as a random effect
SJC swollen joint count, Δ delta values from baseline to 3 months, GS grey scale, GLOESS the OMERACT-EULAR combined score
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sum score, though, was only borderline clinically differ-
ent, but showed a statistically significant difference.
However, the minimal clinically important difference in
sum score for GS and Doppler has yet to be established
and should be tested in subsequent studies.
The strength of the current study is the sample size
and that the analyses include both early and established
RA patients making the findings relevant in clinical
practice. In addition, the two studies used the similar
scoring system based on a US atlas. In the current data-
sets, 28% of the patients had similar clinical findings in
both hands. In such cases, we have no recommendation
regarding which side to choose for longitudinal follow-
up of a unilateral ultrasound score, and the ultrasonog-
rapher may choose freely which side to scan.
Conclusion
No hand is per default more inflamed than its counter-
part. The hand with clinically more swollen joints is
probably the best choice for monitoring ultrasound ac-
tivity in clinical practice and in trials and thus the best
indicator for the side to choose if a unilateral scoring
system is used.
Additional file
Additional file 1: Statistical analysis plan. (PDF 419 kb)
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